Overview

Optimizing Prograf® Therapy in Renal Transplant Patients

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
A study to determine the optimal dose and blood level of Prograf® in long-term maintenance of kidney transplant patients.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma US, Inc.
Treatments:
Tacrolimus